Reaching this threshold in such a compressed timeframe highlights the company’s internal scaling efforts and the steady climb in demand for cell therapy manufacturing. According to CEO Darren Head, the volume reflects a high-intensity collaboration across the firm's manufacturing, quality control, and supply chain departments.
In section Releases
Cellipont Bioservices Hits 100-Batch Milestone in Texas
One hundred Good Manufacturing Practice batches have cleared the floor at Cellipont Bioservices’ Texas facility just thirteen months after the site went live. The rapid output marks a significant operational sprint for the contract manufacturer, which launched its GMP activities in The Woodlands during June 2025.
These teams have managed to sustain rigorous regulatory standards while navigating the complex timelines typical of clinical-stage cell therapy development. For Cellipont, the milestone serves as a benchmark for its expanding infrastructure, which now supports projects ranging from early analytical development to commercial-scale production. As the company continues to refine its facility capabilities, the focus remains on maintaining this throughput to meet the requirements of its growing client base.
Comments (0)
No comments yet. Be the first!